论文部分内容阅读
于1988～1990年间,我们应用IL—2瘤内注射治疗经病理证实的恶性黑色素瘤5例。男3例,女2例。年龄38～68岁,平均56岁。原发灶部位:左拇指甲沟处1例,头颈部3例(口腔颊部,下唇内侧面及左鼻部各1例),右季肋部1例。5例均有原发灶区域淋巴结转移,其中伴肺、脑转移及肺和远隔部位淋巴结转移各1例。5例中有4例有明显交界痣及典型“卫星”结节史。临床分期:Ⅲ期3例,Ⅳ期2例。全部病人以前均接受过以氮烯咪胺为主的联合化疗。治法:治前先测定原发或转移灶大小,然后用 L-21500～4500单位(南京军事医学科研所产,每1ml 1500单位,水剂)施瘤体内注射,隔日1次,12～15次为1
Between 1988 and 1990, we used IL-2 intratumoral injection to treat 5 cases of pathologically confirmed malignant melanoma. There were 3 males and 2 females. Age 38 to 68 years old, average 56 years old. Primary site: 1 case of left thumb nail groove, 3 cases of head and neck (1 case of oral cheeks, inner side of lower lip and left nose), and 1 case of right quarter rib. All 5 cases had primary lymph node metastases, including 1 case with lung, brain metastasis, and lymph node metastasis in the lung and distant sites. Four of the five patients had significant junctional palsy and a history of typical “satellite” nodules. Clinical stage: 3 cases in stage III and 2 cases in stage IV. All patients had previously received chemotherapy with norepinephrine. Governing Law: Before the treatment, the size of the primary or metastatic lesions was measured, and then injected into the tumor with L-21500 to 4500 units (Nanjing Military Medical Research Institute, 1500 units per 1 ml, water), once every other day, 12 to 15 Times 1